Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379

Raw xml | Download


<Evidence xmlns="http://hl7.org/fhir">
  <id value="267236"/>
  <meta>
    <versionId value="9"/>
    <lastUpdated value="2025-12-11T20:35:21.032Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><p class="res-header-id"><b>Generated Narrative: Evidence 267236</b></p><a name="267236"> </a><a name="hc267236"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 9; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-non-comparative-evidence.html">NonComparativeEvidence</a></p></div><p><b>url</b>: <a href="https://fevir.net/resources/Evidence/267236">https://fevir.net/resources/Evidence/267236</a></p><p><b>identifier</b>: FEvIR Object Identifier/267236, FEvIR Linking Identifier/NCT03421379-secondaryOutcomeMeasure-1--OG000</p><p><b>name</b>: NCT03421379_secondaryOutcomeMeasure_1_OG000</p><p><b>title</b>: PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379</p><p><b>citeAs</b>: </p><div><p>PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267236. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267236. Computable resource at: https://fevir.net/resources/Evidence/267236#json.</p>
</div><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>
</div><p><b>note</b>: , </p><blockquote><div><p>Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PD data.</p>
</div></blockquote><blockquote><div><p>Outcome Measure Denominator Units: Participants</p>
</div></blockquote><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG000)</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href="EvidenceVariable-267228.html">PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration -  (NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000574}">median</span></p><p><b>quantity</b>: 1 hour</p><h3>SampleSizes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>KnownDataCount</b></td></tr><tr><td style="display: none">*</td><td>71</td></tr></table><h3>AttributeEstimates</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Full Range</span></td><td>0.5-4.02 hour</td></tr></table></blockquote></div>
  </text>
  <url value="https://fevir.net/resources/Evidence/267236"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="267236"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="NCT03421379-secondaryOutcomeMeasure-1--OG000"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name value="NCT03421379_secondaryOutcomeMeasure_1_OG000"/>
  <title
         value="PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"/>
  <citeAs
          value="PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267236. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267236. Computable resource at: https://fevir.net/resources/Evidence/267236#json."/>
  <status value="active"/>
  <author>
    <name
          value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
  </author>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <description
               value="This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <variableDefinition>
    <description value="Glucagon Nasal Powder"/>
    <note>
      <text
            value="Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PD data."/>
    </note>
    <note>
      <text value="Outcome Measure Denominator Units: Participants"/>
    </note>
    <variableRole value="population"/>
    <observed>
      <identifier>
        <type>
          <text value="ClinicalTrials.gov Outcome Measurement Group Id"/>
        </type>
        <value value="OG000"/>
      </identifier>
      <display
               value="A single dose of 3 mg glucagon nasal powder was administered intranasally"/>
    </observed>
  </variableDefinition>
  <variableDefinition>
    <variableRole value="outcome"/>
    <observed>🔗 
      <reference value="EvidenceVariable/267228"/>
      <type value="EvidenceVariable"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-secondaryOutcome-1"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display
               value="PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration -  (NCT03421379)"/>
    </observed>
  </variableDefinition>
  <statistic>
    <statisticType>
      <coding>
        <system value="https://fevir.net/sevco"/>
        <code value="STATO:0000574"/>
        <display value="median"/>
      </coding>
    </statisticType>
    <quantity>
      <value value="1"/>
      <unit value="hour"/>
    </quantity>
    <sampleSize>
      <knownDataCount value="71"/>
    </sampleSize>
    <attributeEstimate>
      <type>
        <text value="Full Range"/>
      </type>
      <range>
        <low>
          <value value="0.5"/>
          <unit value="hour"/>
        </low>
        <high>
          <value value="4.02"/>
          <unit value="hour"/>
        </high>
      </range>
    </attributeEstimate>
  </statistic>
</Evidence>